PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden. PILA PHARMA is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
XEN-D0501 was in-licensed in 2016 and was prior to that found to be safe in people without diabetes. The maximal tolerable dose in this population was set to bi-daily doses of 4 mg.
Pila Pharma
